Sun Pharma included in 2026 S&P Dow Jones Best-in-Class World Index
Inclusion based on S&P Global sustainability assessment covering global companies across markets
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Sun Pharmaceutical Industries
Panel Discussion: Aligning packaging strategies with R&D
At the recently held PPL Conclave 2025 in Hyderabad, a panel discussion titled "Aligning Packaging Strategies with R&D"…
Formulation strategies for complex injectables
At the FDD Conclave 2025, Dr. Ajay Jaysingh Khopade, VP FR&D, Sun Pharmaceutical Industries, delivered an insightful…
Sun Pharma launches corporate brand campaign in India
The brand activations will extend to doctors, pharmacists and distributors across India
Sun Pharma and Moebius Medical publish clinical and mechanistic data on non-opioid knee…
Phase 2b study and supporting research highlight MM-II’s potential in symptomatic knee osteoarthritis; new findings presented at…
Taro shareholders approve merger with Sun Pharma
Upon the completion of merger Taro will become a privately held company wholly owned by Sun Pharma
Sun Pharma gets approval for Winlevi in Australia
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Sun Pharma included in S&P Global Sustainability Yearbook 2024
Over 9,400 companies were assessed for The Sustainability Yearbook 2024. Out of these, 739 companies have qualified for inclusion…
Bayer, Sun Pharma sign marketing and distribution pact for second brand of Finerenone
Sun Pharma to market the drug under the brand name Lyvelsa
Nidlegy Phase III PIVOTAL trial shows postive results for patients with locally advanced fully…
Intratumoral Nidlegy followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone